A phase 1/2 trial of CRB-701 in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors is a phase 1/2 interventional study registered as NCT06265727 by Corbus Pharmaceuticals Inc., with 348 participants planned, started 2024-04-01 and due to reach its primary completion in 2027-01-16. Interventions recorded: CRB-701 and Anti-PD-1.
Shares Corbus Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.